Over 20 types of HER2 exon 20 insertion (ex20ins) mutations have been identified in NSCLC, accounting for 25–50% of NSCLC patients exhibiting HER2 mutations [4, 5, 6]. Here, ERBB2 is linked to non-small cell lung carcinoma.